-
Efficacy & safety of Mitoxantrone Liposome in treating peripheral T-cell lymphomas: A real-world study (MOMENT)
Efficacy and safety of mitoxantrone hydrochloride liposome injection in treatment of peripheral T-cell lymphomas: a multicenter, non-interventional, ambispective cohort, real-world study (MOMENT) In August 2023, Professor Jun Ma and his…
-
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies
The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year’s AACR conference, three clinical trials were reported…
-
Dr. Lu Si: mRNA Vaccines and TIGIT Monoclonal Antibodies — New Stars of 2023 AACR
PD-1 inhibitors have become the international standard for adjuvant treatment of stage IIB-IV melanoma after surgery. Research on the neoadjuvant use of PD-1 monotherapy (pembrolizumab) for resectable melanoma was just published in the New England Journal of Medicine in March of this year. With this, PD-1 inhibitors cover the two major treatment areas of neoadjuvant…
-
🩸🇨🇳💡Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research
Professor Jun Ma and his team from Harbin Institute of Hematology Oncology published in May 2023 in the Chinese Journal of Hematology titled “Current status of diagnosis and treatment of…
-
Combining PD-1 Monoclonal Antibody and HDAC Inhibitor with Conventional P-Gemox Significantly Improves the Treatment Outcome for NK/T Cell Lymphoma
From June 17th to 23rd, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held grandly in Lugano, Switzerland. As the world’s largest conference on malignant lymphoma, ICML has become an essential event in the field of lymphoma research and treatment over the past decades, aiming to present and discuss the latest basic, translational,…
-
ILTS 2023｜Shifting Paradigms in Radiological Assessment of Tumor Load in Liver Transplantation for HCC
Liver transplantation is a crucial option for treating Hepatocellular Carcinoma (HCC) as it not only removes the tumor but also addresses underlying liver disease. Accurate prediction of post-transplantation outcomes for patients with HCC tumors exceeding MELD standards or awaiting transplantation due to donor shortages is essential to enhance surgical success rates and optimize liver allocation.…
-
ILTS 2023 | New Approach for Early Detection of Hepatocellular Carcinoma – Biophysical Characteristics of Tumor Tissue and Serum
Biological physics is an interdisciplinary field that combines physics with biology, serving as an important branch of both life sciences and physics. Its aim is to elucidate the laws governing the motion of matter, energy, and information in biological systems within specific spatial and temporal contexts. However, the potential role of biophysical techniques in early…
-
ILTS 2023 | Liver Resection or Thermal Ablation as a Bridge to Liver Transplantation for Hepatocellular Carcinoma – DELTAS-HCC Study
Liver transplantation is one of the curative treatment options for hepatocellular carcinoma (HCC). However, due to the limited availability of liver donors compared to the number of patients awaiting transplantation, only a small number of HCC patients can receive liver transplantation. Previous studies have shown that local treatment before liver transplantation in HCC patients can…
Connecting Medical Expertise through Media